VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DSGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DSGNDesign Therapeutics, Inc.
$9.47$591M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksDSGNCash Flow

Design Therapeutics, Inc. (DSGN) Cash Flow Statement

7Y historyFree accessUpdated daily

Operating cash flow has tracked 66% to 95% of net loss, with free cash flow of -$15.4M in 2026Q3 and no dividends, buybacks, or acquisitions, meaning all operating burn must be funded externally.

Income StatementBalance SheetCash FlowRatios

DSGN Cash Flow Statement

Annual statement

DSGN Cash Flow Statement

Design Therapeutics, Inc. (DSGN) cash flow statement — 7-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Cash from Operations-59.3M-54.36M-43.1M-58.56M-51.32M-29.38M-8.67M-139K
Operating CF Margin %--------16666.67%
Operating CF Growth %-64.5%-26.11%26.39%-14.11%-74.68%-238.87%-6136.69%-
Net Income-74.09M-69.79M-49.59M-66.86M-63.31M-35.53M-8.28M-2.05M
Depreciation & Amortization457K622K596K537K406K129K5K1.91M
Stock-Based Compensation15.28M14.55M13.07M13.09M10.93M4.69M450K0
Deferred Taxes00000000
Other Non-Cash Items-376K-2.85M-6.19M-6.05M-1.33M-58K-33K-1.81M
Working Capital Changes-571K3.11M-993K728K1.99M1.4M-811K1.81M
Change in Receivables00000000
Change in Inventory00000000
Change in Payables1.73M4.49M-1.22M-1.25M5.38M2.41M-413K0
Cash from Investing-3.93M22.91M43.95M52.54M-220.99M-53.64M-33.56M0
Capital Expenditures-70K-193K-340K-256K-918K-1.54M-76K0
CapEx % of Revenue--------
Acquisitions000039K52.11K00
Investments--------
Other Investing00000-52.11K00
Cash from Financing63.39M25.74M513K724K235K379.21M44.53M196K
Debt Issued (Net)000000-200K196K
Equity Issued (Net)63.39M25.74M513K724K662K378.98M44.73M0
Dividends Paid00000000
Share Repurchases00000000
Other Financing0000-427K228K1K0
Net Change in Cash164K-5.71M1.36M-5.3M-272.07M296.19M2.3M57K
Free Cash Flow-59.37M-54.55M-43.45M-58.82M-52.23M-30.91M-8.74M-139K
FCF Margin %--------16666.67%
FCF Growth %-13.28%-25.56%26.13%-12.6%-68.96%-253.52%-6191.37%-
FCF per Share-0.94-0.95-0.77-1.05-0.94-0.67-0.32-0.01
FCF Conversion (FCF/Net Income)0.80x0.78x0.87x0.88x0.81x0.83x1.05x0.07x
Interest Paid00000024K0
Taxes Paid00000000

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Limited cash runway

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Burn Tracks Losses Closely

According to the reported cash flow statement, DSGN's operating cash flow has run between roughly 66% and 95% of reported net loss over the ten quarters shown, indicating that the bulk of the accounting loss is a real cash outflow rather than a non-cash charge.

The operating cash flow to net income ratio ranges from 0.66 in 2025Q3 to 0.95 in 2024Q2 and 2025Q1, meaning net losses are not being materially cushioned by accruals. Stock-based compensation of $3.1M to $4.1M per quarter explains only part of the gap, so the remaining cash burn appears driven by clinical and R&D spending. This suggests the earnings quality concern is less about accrual manipulation and more about the pace at which cash is consumed by development activity.

Free Cash Flow Deficit Widened Into 2026

As reported in the cash flow statements, DSGN's free cash flow deteriorated from roughly -$9.5M in 2024Q3 to -$15.4M in 2026Q3, with negligible capital expenditure contributing to the trend.

Because capital expenditure is near zero in nearly every quarter, free cash flow is effectively equal to operating cash flow, and the deficit is entirely an operating phenomenon. The approximately 60% increase in quarterly burn over two years appears consistent with an expanding clinical program rather than deteriorating unit economics. Investors should monitor whether the burn rate is stabilizing or continuing to accelerate as later-stage trials scale.

Working Capital Swings Mask Underlying Burn

Based on DSGN's reported figures, working capital changes have alternated between large outflows of -$2.8M in 2026Q1 and inflows of up to $2.9M in 2025Q3, creating quarter-to-quarter volatility that obscures the underlying cash trend.

These swings appear to reflect timing of payables and prepaid clinical commitments rather than changes in operating efficiency, given the absence of revenue or inventory. The 2026Q1 outflow coincided with the sharpest quarterly operating burn in the period, suggesting that some expense recognition may have been pulled forward or settled in that quarter. Analysts should look at trailing averages rather than individual quarters to isolate the true run-rate.

No Shareholder Returns Amid Equity Dependence

DSGN reported zero dividends, buybacks, or acquisition spending across all ten quarters, so every dollar of cash consumed by operations must be funded externally.

The absence of capital returns is expected for a pre-revenue biotech, but it means the company's entire capital structure exists to fund clinical development. The reported 0.01 debt-to-equity ratio alongside negative ROE of -30.7% suggests reliance on equity issuance rather than leverage. Based on reported figures, the financing requirement warrants further investigation as the quarterly operating burn of roughly $15M to $16M appears to outpace the last disclosed cash balance of $16.9M.

Cash Flow Data Gaps Limit Runway Assessment

The cash flow data provided does not include a current cash balance, so runway estimates rely on a previously reported $16.9M figure against quarterly burn near $15.4M.

If the most recent cash position is close to the prior disclosure, the implied runway would be roughly one quarter at current burn rates, a conclusion that appears to warrant urgent review of the balance sheet. Alternatively, undisclosed financing transactions after the last reported balance may have extended liquidity, and that possibility cannot be ruled out from the supplied data. Investors should treat the absence of a current cash figure as a material gap rather than assume either outcome.

DSGN — Frequently Asked Questions

Quick answers to the most common questions about buying DSGN stock.

How much cash does Design Therapeutics, Inc. (DSGN) generate from operations?

Design Therapeutics, Inc. (DSGN) generated $-54.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Design Therapeutics, Inc.'s free cash flow?

Design Therapeutics, Inc. (DSGN) reported negative free cash flow of $54.6M in 2025, indicating capital requirements exceeded cash from operations.

What is Design Therapeutics, Inc.'s capital expenditure (CapEx)?

Design Therapeutics, Inc. (DSGN) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.